An emerging technique for the dual‑targeting chemo‑radio‑ablation of generic micro‑cancers in conjunction with cancer liquid biopsy
Affiliations: Theragnostic Laboratory, Department of Imaging and Pathology, Faculty of Medicine, Biomedical Group, KU Leuven, 3000 Leuven, Belgium
- Published online on: December 23, 2022 https://doi.org/10.3892/or.2022.8472
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Cancer liquid biopsy (CLB) aims for the detection of circulating tumor cells, cell‑free DNA or RNA, and specifically expressed proteins, lipids and metabolites present in the bio‑fluids of patients. Rapid advances in technologies for sampling such bio‑specimens and for genomic sequencing have fostered the development of authority‑approved CLB tests in clinical practice for the early screening and diagnosis of malignancies. However, perhaps some solid tumors could have been reliably detected using CLB, while they were still too small to be found in patients using currently available imaging technologies. This could impose troublesome clinical scenarios. In this communication article, the author would like to propose a potential solution that eventually may be used to combat such unwanted embarrassing clinical issues by using one episode of targeted radiotheragnostics, namely OncoCiDia.